about
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastGene from a psoriasis susceptibility locus primes the skin for inflammationNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsThe role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritisOverrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis.Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS eraSelf-association of an activating natural killer cell receptor, KIR2DS1Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis.IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesisEffects of artemether on the proliferation, apoptosis, and differentiation of keratinocytes: potential application for psoriasis treatment.Cutaneous microdialysis: cytokine evidence for altered innate reactivity in the skin of psoriasis patients?The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasisExpression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitorPsoriatic disease and tuberculosis nowadays.Antipsoriatic effects of avarol-3'-thiosalicylate are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin.Calcipotriol/betamethasone dipropionate for the treatment of psoriasis.Emerging drugs for psoriasis.The evolution of the psoriatic lesion.Stress-induced neurogenic inflammation in murine skin skews dendritic cells towards maturation and migration: key role of intercellular adhesion molecule-1/leukocyte function-associated antigen interactions.Interleukin-20 as a target in psoriasis treatment.MicroRNAs: novel regulators in skin inflammation.Inflammasomes and inflammatory caspases in skin inflammation.NK cell autoreactivity and autoimmune diseases.Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis.Targeting signaling pathways with small molecules to treat autoimmune disorders.Natural killer cells in psoriasis.NK cells and psoriasis.The role of natural killer cells in autoimmune blistering diseases.Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.Bimodal immune activation in psoriasis.Differential regulation of surface receptor expression, proliferation, and apoptosis in HaCaT cells stimulated with interferon-γ, interleukin-4, tumor necrosis factor-α, or muramyl dipeptide.Nuclear envelope localization of Ran-binding protein 2 and Ran-GTPase-activating protein 1 in psoriatic epidermal keratinocytes.Expression and functional studies on the noncoding RNA, PRINS.Overexpression of CXCL16 in lesional psoriatic skin.Genetic polymorphisms of NFκB1 -94 del/ins ATTG, NFκB1A 2758 A>G and SUMO rs237025 G>A in psoriasis.Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients.Abnormal regulation of fibronectin production by fibroblasts in psoriasis.A child with psoriasis, hypogammaglobulinemia, and monosomy 7-positive myelodysplastic syndrome.Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression.
P2860
Q22305855-F4A8DE53-4CCC-42B8-AEEF-278ECB7398B2Q24314913-20491EC6-04B0-408D-BA24-8BAB0E754337Q26800937-52091D72-F5B8-4EF5-B455-C8BCF00A1D7CQ26821943-AC0D7604-C8FA-4752-8F64-A10ACCD7C944Q33760897-11DA7531-8368-4806-9167-A6030A6907F8Q33768338-9E7D25ED-10EB-4CD9-BCE8-79CF2BE3CEFEQ34017545-9EEF086E-1905-4C82-830B-BE2D94037486Q34091087-FD3773EC-6E4D-41D5-9BE6-261C33982D0EQ34114368-1FABDD30-9E60-46D5-894C-4456294AEDB1Q34577866-E6902475-8D51-4A35-9CD6-CBA01D8F026DQ35870660-6D39F2D0-6F29-4601-9D44-1CB3E6B92DCBQ35888376-46AB2DCC-A3F1-44F5-98DD-EAD6B80E31ABQ35928147-5C76674F-2065-4C7D-BD0C-141B40CB3F80Q35945026-C9A79EBB-3260-440B-88C1-46EC965D6026Q35974892-377E0373-44F0-4507-ACAD-89174A00BF74Q36094366-1FC807DE-0D53-4F3E-8290-6111C87D91AFQ36428510-C8711757-D953-45B4-A58C-7D4085781F66Q36634244-D8A3F2D0-A971-4999-B593-6007A4781BA8Q36853157-ACCDA99E-FB78-42D3-B1D9-13FD4F90EEFFQ36943066-0570BA65-1A49-4F5B-B63D-F7E0E39C1980Q36958344-5AA22CDA-F752-4D81-AA40-5F48B27E84ADQ37141220-01D6D6ED-9BA7-4BE4-B64D-686FB37002EAQ37322440-38463C4E-B89B-4524-82E8-1B3567B5C779Q37552129-B88087BC-9567-41EF-B3F6-3A4AB2CFD4AAQ37694579-824784F8-F5FF-499B-9E39-48E4CA0F9A6CQ37755216-572BED70-5216-438C-964B-64DBA4A524DFQ37879879-F58531C2-8AD1-47C2-8041-F9C56F16944DQ37891799-1C82FEA8-0355-4F6D-B6E3-704772ED14FCQ37933429-CCC2A20F-F166-41C1-895B-342425DECB40Q38032568-6C4BB9EB-6649-4919-AFAC-D234C99CE059Q38151778-3D476038-E503-4D62-85F5-F2A9176520A4Q38705832-5B60C5EC-09DA-417C-B01C-338548D2FB66Q39033448-FB0A54B2-2DD5-4ECA-9C25-4059A48C6C5EQ39205933-8F9FAA5D-382A-482F-96B9-87396933937EQ39533961-173941BD-3744-4C3D-84B4-BA8E5B0BC81AQ39570426-B3D8FB31-C2C5-4936-B457-7AAA25F77795Q40117550-9D2FB8EE-0CC7-4AC8-8D4B-2CF78FD5FBB9Q40427057-8FD74C09-8C41-4FE3-9CC2-EE897A6B1690Q40921798-D3E26D72-7402-4E28-9D64-BC014EB8433CQ42142254-BFBC012F-7473-4B5F-BA22-E20E24C3CE9F
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Psoriasis: dysregulation of innate immunity.
@ast
Psoriasis: dysregulation of innate immunity.
@en
type
label
Psoriasis: dysregulation of innate immunity.
@ast
Psoriasis: dysregulation of innate immunity.
@en
prefLabel
Psoriasis: dysregulation of innate immunity.
@ast
Psoriasis: dysregulation of innate immunity.
@en
P2093
P1476
Psoriasis: dysregulation of innate immunity.
@en
P2093
P304
P356
10.1111/J.1365-2133.2005.06645.X
P407
P577
2005-06-01T00:00:00Z